Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are the most common form of neuroendocrine neoplasia, but there is no current consensus for the sequencing of approved therapies, particularly with respect to peptide receptor radionuclide therapy (PRRT). Surgical resection is recognized as the only clinically curative measure for GEP-NETs; however, given that these tumors have a propensity to metastasize and the primary tumor may, in some cases, be unresectable, various treatment options have been introduced including PRRT. This review evaluates the data supporting approved therapies for GEP-NETs and the current recommendations for therapeutic sequencing with a focus on PRRT and how sequencing might change with respect to the increasing body of literature regarding PRRT utilization.